Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.73 | -0.18 | 0.57 | 0.04 |
| FCF Yield | -3.84% | -4.05% | -6.67% | -7.14% |
| EV / EBITDA | -22.39 | -17.11 | -15.73 | -15.03 |
| Quality | ||||
| ROIC | -8.79% | -8.96% | -7.01% | -7.09% |
| Gross Margin | 86.96% | 76.23% | 87.57% | 88.26% |
| Cash Conversion Ratio | 0.85 | 0.69 | 1.25 | 1.38 |
| Growth | ||||
| Revenue 3-Year CAGR | 23.07% | 26.59% | 24.88% | 36.85% |
| Free Cash Flow Growth | -15.01% | 30.52% | 16.31% | -58.48% |
| Safety | ||||
| Net Debt / EBITDA | 0.47 | 0.29 | 0.25 | 0.16 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.05 | 0.10 | 0.04 | 0.05 |
| Cash Conversion Cycle | 704.16 | 440.77 | 1,351.64 | 818.25 |